Synexus Clinical Research PLC
22 December 2006
SYNEXUS CLINICAL RESEARCH PLC
TOTAL VOTING RIGHTS AND CAPITAL
In conformity with the Transparency Directive's transitional provision 6,
Synexus Clinical Research plc (the "Company") would like to notify the market
that the capital of the Company consists of 23,154,172 ordinary shares with a
nominal value of 10p each, with voting rights.
The Company does not hold any ordinary shares in Treasury.
Therefore, the total number of voting rights in the Company is 23,154,172 (the
"Figure").
The Figure may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their interest in,
or a change to their interest in the Company under the FSA's Disclosure and
Transparency Rules.
For further enquiries please contact the Chief Financial Officer:
Paul McCluskey (01257 230723)
Ends
This information is provided by RNS
The company news service from the London Stock Exchange